Search results
Results from the WOW.Com Content Network
Americans without health insurance pay an average of $98 for Eli Lilly’s generic insulin despite the company’s May 1 pledge to cut its list price to $25 per vial, according to a survey of more ...
The Federal Trade Commission took action Friday against the nation’s three largest pharmacy benefit managers, accusing the companies of artificially inflating insulin list prices that resulted ...
Toggle Antipsychotics subsection. 1.1 Antipsychotic esters. 1.1.1 Typical antipsychotics. 1.1.2 Atypical antipsychotics. 2 See also. 3 References. 4 External links.
"Insulin is an extreme case of PBMs extracting bigger and bigger rebates from drug manufacturers and driving list prices up at the pharmacy counter, but this is a dynamic that plays out with many ...
Recently, the FDA required the manufacturers of some atypical antipsychotics to include a warning about the risk of hyperglycemia and Type II diabetes with atypical antipsychotics. Some evidence suggests that ziprasidone does not cause insulin resistance to the degree of other atypical antipsychotics, such as olanzapine. Weight gain is also ...
Chlorpromazine was developed in 1950 and was the first antipsychotic on the market. [ 7 ] [ 8 ] It is on the World Health Organization's List of Essential Medicines . [ 9 ] [ 10 ] Its introduction has been labeled as one of the great advances in the history of psychiatry .
The price of Levemir, a long-acting insulin, will be reduced by 65% to $107.85 per vial and $161.77 per pen, the company said. Novolin will see a similar price reduction, at $48.20 per vial and ...
Blonanserin, sold under the brand name Lonasen, is a relatively new atypical antipsychotic (approved by PMDA in January 2008) [2] commercialized by Dainippon Sumitomo Pharma in Japan and Korea for the treatment of schizophrenia. [3]